Elanco Animal Health Incorporated (ELAN) Stock

Elanco Animal Health Incorporated (ELAN) is a Healthcare stock trading at $23.98 (as of 2026-08-21), with a market capitalization of $11.98B and a trailing P/E of 89.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Elanco Animal Health Incorporated develops, manufactures, and markets animal health products for companion animals and livestock. Its offerings include preventive treatments, therapeutics, and vaccines for pets, plus products for poultry, aquaculture, ruminants, and swine, sold through distributors, veterinarians, and farm animal producers.

Understand Elanco Animal Health Incorporated: how it makes money

Elanco makes animal health products for pets and farm animals, including parasiticides and vaccines for prevention, therapeutics for conditions in dogs and cats, and products such as vaccines and antibiotics for poultry and aqua, sold through pet and veterinary channels and farm animal markets.

Profitability is driven by the sales mix of branded pet and farm animal products, where new product growth and demand are reflected in veterinary clinic adoption and repeat purchasing behavior (for example, Zenrelia reorder and Credelio Quattro clinic penetration), while legacy portfolio trends show up in base revenues for brands such as Seresto and the Advantage family.

Revenue by segment (latest quarter)
Pet Health$0.7B
Farm Animal$0.6B
Contract and Other$0.0B

Business quality (Mixed): The provided facts clearly show Elanco's product categories (pet and farm), a workable segment split for the latest quarter, and several adoption and repeat-purchase operating metrics tied to newer brands, but there is no full profitability bridge or guidance data here to validate how those metrics translate into future earnings.

Bull case

  • Multi-category portfolio across pets and farms: Revenue spans Pet Health (including prevention products like parasiticides and vaccines) and Farm Animal (including products such as vaccines and other medicines for poultry and aqua).
  • Innovation has measurable commercial traction signals: Operating metrics provided include clinic adoption and reorder behavior for newer products, such as Zenrelia reorder rate and Credelio Quattro clinic penetration.
  • Brands supported by repeat use: The presence of prevention products (for worms, fleas, and ticks) and the inclusion of reorder rate as an operating metric suggest demand durability can matter for results.

Bear case

  • Dependence on legacy brand performance: The facts separately track legacy products such as Seresto and the Advantage family, and they also reference declines for Seresto and an advanced family of products.
  • New products must convert into sustained clinic adoption: Key operating metrics focus on penetration, adoption, and share in clinics carrying products, so slower adoption or less repeat behavior could affect growth.
  • Operating margins can be pressured even with high gross margin: Latest quarter operating margin is provided (6.3%), which highlights that operating expenses and other items can limit how much gross margin becomes operating profit.
Valuation — source: SEC EDGAR (first-party)
Price$23.98
Market Cap$11.98B
P/E Ratio89.4
EV / EBITDA26.1
Price / Book1.82
Price / Sales2.28
FCF Yield3.1%
DCF Value (model)$11.97
DCF Upside vs Price-50.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$4.71B
Net Margin-4.9%
Revenue Growth (YoY)6.2%
EPS Growth (YoY)-169.1%
FCF Growth (YoY)-27.9%
Financial Health — source: SEC EDGAR
Altman Z-Score1.29 (distress)
Piotroski F-Score5/9 (moderate)
Valuation vs Sector & Industry
Stock P/E89.4
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
vs Sector311.3%
vs Industry420.6%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderDodge & Cox ($1.65B)
Institutional Holders Tracked10
Congressional Trades (recent)8
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJeffrey N. Simmons
Employees9,000
CountryUS
IPO Date2018-09-20

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Alnylam Pharmaceuticals, Inc. (ALNY)
  • Organon & Co. (OGN)
  • Amneal Pharmaceuticals, Inc. (AMRX)
  • Royalty Pharma plc (RPRX)
  • Sarepta Therapeutics, Inc. (SRPT)
  • PTC Therapeutics, Inc. (PTCT)
  • Viatris Inc. (VTRS)
  • Phibro Animal Health Corporation (PAHC)
ELAN earnings history · ELAN institutional & insider holders · ELAN KPIs & operating metrics · ELAN financials · ELAN investor presentations & press releases · ELAN SEC filings · ELAN peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.